Photo of Steven R. Tahan,  MD

Steven R. Tahan, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-4344
Fax: (617) 754-7120

Steven R. Tahan, MD

Beth Israel Deaconess Medical Center


  • Associate Professor, Pathology, Harvard Medical School
  • Director, Dermatopathology, Beth Israel Deaconess Medical Center


Research Abstract

Dr. Tahan's research interests are the identification of genes and their products important in the progression of melanocytic lesions, and the identification of biologic markers of aggressiveness/prognosis in melanoma and other human skin neoplasms. Recent work includes: 1. Discovery of autocrine regulatory function of CXCL10 and its receptor dependency on melanoma growth rate and invasiveness, and investigation of molecular mechanisms of this action. 2. Demonstration of stem cell marker expression among subpopulation of melanoma cells,

3. Studying molecular changes in human Kaposi's sarcoma associated with regression after treatment with Taxol derivatives and anti-angiogenetic agents.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Stagner AM, Tahan SR, Nazarian RM. Changing Trends in Dermatopathology Case Complexity: A 9-Year Academic Center Experience. Arch Pathol Lab Med 2020. PubMed
  • Okhovat JP, Tahan SR, Kim CC. A pink enlarging plaque on the plantar foot: amelanotic acral lentiginous melanoma. Dermatol Online J 2019. PubMed
  • Wong V, Cheng CE, Tahan SR, Kim CC. Carcinoma erysipeloides of papillary serous ovarian cancer mimicking cellulitis of the abdominal wall. Cutis 2018; 101:E9-E10. PubMed
  • Yeh JE, Tahan SR, Burgin S. Folliculin mutation-negative trichodiscomas in a patient with multiple endocine neoplasia type I syndrome. Dermatol Online J 2017. PubMed
  • Clarke LE, Warf BM, Flake DD, Hartman AR, Tahan S, Shea CR, Gerami P, Messina J, Florell SR, Wenstrup RJ, Rushton K, Roundy KM, Rock C, Roa B, Kolquist KA, Gutin A, Billings S, Leachman S. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol 2015; 42:244-52. PubMed
  • Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol 2014; 150:307-11. PubMed
  • Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Telaprevir-Related Dermatitis. Arch Dermatol 2012. PubMed
  • Chan MP, Chan MM, Tahan SR. Melanocytic nevi in pregnancy: histologic features and Ki-67 proliferation index. J Cutan Pathol 2010; 37:843-51. PubMed
  • Sepehr A, Wenson S, Tahan SR. Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus. J Cutan Pathol 2010; 37 Suppl 1:112-24. PubMed
  • Chan MM, Tahan SR. Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas. J Cutan Pathol 2010; 37:336-43. PubMed
  • Negin B, Panka D, Wang W, Siddiqui M, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res 2008; 14:654-9. PubMed
  • Medeiros LC, Morais MB, Tahan S, Fukushima E, Motta ME, Fagundes-Neto U. [Clinical characteristics of pediatric patients with chronic constipation according to age group] Arq Gastroenterol 2007; 44:340-4. PubMed
  • Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007; 20:102-7. PubMed
  • Pantanowitz L, Dezube BJ, Hernandez-Barrantes S, Tahan SR, Dabbous MK. Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol 2006; 33:793-8. PubMed